Bagel, J.; Armstrong, A. W.; Warren, R. B.; Papp, K. A.; Thaçi, D.; Menter, A.; Cather, J.; Augustin, M.; Hippeli, L.; Daamen, C.; Griffiths, C. E. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy by Prior Treatment in the Phase 3 POETYK PSO-1 Trial. J of Skin 2023, 7, s117.